IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial
1. 系统已在2025-03-31 16:22:53对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.medj.2024.100573
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S2666634024004872
其他信息:
出版社: Elsevier BV
作者: Huayi Li; Yu Xu; Xiaofei Jiao; Qin Xu; Zikun Peng; Ying Tang; Jieqing Zhang; Bowen Huang; Yiyang Shen; Baoping Chang; Bairong Xia; Wei Duan; Danbo Wang; Lijing Zhu; Ruifang An; Guonan Zhang; Yaling Tang; Jianli Huang; Hui Qiu; Li Wang; Yi Huang; Guiling Li; Jianhua Qian; Li Sun; Hong Zheng; Ge Lou; Youzhong Zhang; Youguo Chen; Liqin Lu; Yan Cheng; Jihong Liu; Weidong Zhao; Jianghai Ji; Aiqin He; Ke Wang; Guohua Yu; Hong Zhu; Cailing Ma; Jianlin Yuan; Xia Wang; Hongfei Zhang; Xinyan Ma; Chujun Cai; Kang Yin; Han Xie; Ya Wang; Shuyan Wang; Li Li; Hui Zhou; Jing Wang; Jianqing Zhu; Ding Ma; Qinglei Gao
